nach oben

Current Dermatology Reports

Erschienen in:

06.12.2019 | Hospital-Based Dermatology (L Guggina and A Zhou)

Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: a Review and Update

verfasst von: Jennifer L. Coias, Laila F. Abbas, Adela R. Cardones

Erschienen in: Current Dermatology Reports | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review highlights current concepts in the management of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN).

Recent Findings

A new scoring system, the ABCD-10, was recently developed to better estimate mortality among SJS/TEN patients. Supportive care remains the mainstay of treatment, and includes wound care, fluid and electrolyte management, management of medical co-morbidities, and infection control. The value of adjuvant therapy remains unclear, but new recent retrospective studies suggest that the combination therapies may be efficacious. Recent prospective studies investigating cyclosporine and etanercept have shown promise in the treatment of SJS/TEN.

Summary

SJS and TEN are severe mucocutaneous drug reactions associated with high morbidity and mortality. Supportive care is the most universally accepted therapy, although specific strategies may vary among institutions. Adjuvant therapies include corticosteroids, IVIG, cyclosporine, TNF alpha inhibitors, and plasmapheresis but prospective data is still lacking. Clinical trials that may better elucidate their efficacy are currently under way.

Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92–6.PubMedCrossRef

Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol. 2005;94(4):419–36; quiz 36–8, 56. https://doi.org/10.1016/S1081-1206(10)61112-X.PubMedCrossRef

Goodman H. Nikolsky sign; page from notable contributors to the knowledge of dermatology. AMA Arch Derm Syphilol. 1953;68(3):334–5.PubMedCrossRef

Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5:39. https://doi.org/10.1186/1750-1172-5-39.PubMedPubMedCentralCrossRef

• Jun I, Rim JH, Kim MK, Yoon KC, Joo CK, Kinoshita S, et al. Association of human antigen class I genes with cold medicine-related Stevens-Johnson syndrome with severe ocular complications in a Korean population. Br J Ophthalmol. 2019;103(4):573–6. https://doi.org/10.1136/bjophthalmol-2018-313263This multicentre case-control study found significant difference in gene frequency for HLA-A*02:06 (37% vs 20%) and HLA-C*03:04 (15% vs 5.4%) in patients with SJS/TEN patients compared with age, sex matched controls, respectively. PubMedCrossRef

Nicoletti P, Barrett S, McEvoy L, Daly AK, Aithal G, Lucena MI, et al. Shared genetic risk factors across carbamazepine-induced hypersensitivity reactions. Clin Pharmacol Ther. 2019. https://doi.org/10.1002/cpt.1493.CrossRef

Correia O, Delgado L, Ramos JP, Resende C, Torrinha JA. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. Arch Dermatol. 1993;129(4):466–8.PubMedCrossRef

Paul C, Wolkenstein P, Adle H, Wechsler J, Garchon HJ, Revuz J, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol. 1996;134(4):710–4.PubMedCrossRef

Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science (New York, NY). 1998;282(5388):490–3. https://doi.org/10.1126/science.282.5388.490.CrossRef

10.

Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol. 2004;114(5):1209–15. https://doi.org/10.1016/j.jaci.2004.07.047.PubMedCrossRef

11.

Wei CY, Chung WH, Huang HW, Chen YT, Hung SI. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol. 2012;129(6):1562–9 e5. https://doi.org/10.1016/j.jaci.2011.12.990.PubMedCrossRef

12.

Genin E, Schumacher M, Roujeau JC, Naldi L, Liss Y, Kazma R, et al. Genome-wide association study of Stevens-Johnson syndrome and toxic epidermal Necrolysis in Europe. Orphanet J Rare Dis. 2011;6:52. https://doi.org/10.1186/1750-1172-6-52.PubMedPubMedCentralCrossRef

13.

Borchers AT, Lee JL, Naguwa SM, Cheema GS, Gershwin ME. Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev. 2008;7(8):598–605. https://doi.org/10.1016/j.autrev.2008.06.004.PubMedCrossRef

14.

Rzany B, Mockenhaupt M, Baur S, Schroder W, Stocker U, Mueller J, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol. 1996;49(7):769–73.PubMedCrossRef

15.

Strom BL, Carson JL, Halpern AC, Schinnar R, Snyder ES, Shaw M, et al. A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures. Arch Dermatol. 1991;127(6):831–8.PubMedCrossRef

16.

Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126(1):43–7.PubMedCrossRef

17.

Roujeau JC, Chosidow O, Saiag P, Guillaume JC. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol. 1990;23(6 Pt 1):1039–58.PubMedCrossRef

18.

Schopf E, Stuhmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol. 1991;127(6):839–42.PubMedCrossRef

19.

• Frey N, Jossi J, Bodmer M, Bircher A, Jick SS, Meier CR, et al. The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. J Invest Dermatol. 2017;137(6):1240–7. https://doi.org/10.1016/j.jid.2017.01.031This large obersvational study of over 500 patients from the UK calculated an incidence of 5.76 SJS/TEN cases per million person-years between 1995 and 2013. They found black and Aisian patients to be at 2-fold risk. They observed increased odds for patients with epilepsy and gout who were taking a antiepileptics or allopurinol. They also observed assosciations with pre-existing depresion, lupus erythematosus, pneumonia, kidney disease, and cancer. PubMedCrossRef

20.

• Yang MS, Lee JY, Kim J, Kim GW, Kim BK, Kim JY, et al. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis: a nationwide population-based study using national health insurance database in Korea. PLoS One. 2016;11(11):e0165933. https://doi.org/10.1371/journal.pone.0165933This Korean population-based study obtained records of 938 SJS cases and 229 TEN cases between 2009 and 2013. They observed an incidence of 3.96–5.03 and 0.94 to 1.45 in SJS and TEN, respectively. Incidence was relatively stable for each year of the study. In hosptial mortality was 5.7% for the patients with SJS and 15.1% for the patients with TEN. PubMedPubMedCentralCrossRef

21.

Naegele D, Sekula P, Paulmann M, Mockenhaupt M. Incidence of Stevens-Johnson syndrom/toxic epidermal necrolysis: results of 10 years from the German registry. Pharmacoepidemiol Drug Saf. 2017;26:3.

22.

• Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol. 2016;136(7):1387–97. https://doi.org/10.1016/j.jid.2016.03.023This US cohort consisted of 2591 patients with SJS, 502 with SJS/TEN overlap, and 564 with TEN from a nationwide inpatient sample between 2009 and 2012. The estimated incidences were 9.2, 1.6, and 1.9 per million adults per year, respectively. There was increased odd for Asian (OR 3.27) and black (OR 2.01) patients. Mean adjusted mortality was 4.8% for SJS, 19.4% for overlap, and 14.8% for TEN. PubMedCrossRef

23.

• Micheletti RG, Chiesa-Fuxench Z, Noe MH, Stephen S, Aleshin M, Agarwal A, et al. Stevens-Johnson syndrome/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States. J Invest Dermatol. 2018;138(11):2315–21. https://doi.org/10.1016/j.jid.2018.04.027This multi-center retrospective study of 377 patients with SJS/TEN positviely identified a medications as the cause for 89.7% of patients, most often trimethoprim/sulfamethoxazole (26.3%). Most patients were managed in the intensive care or burn unit and most received pharmacologic therapy compared with supportive care alone. The in-hospital mortality was lower (54 deaths) than predicted by SCORTEN (78 deaths). Standardized mortality ratio (0.52) was lowest for patients receiving combination IVIg and corticosteroids. PubMedCrossRef

24.

Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol. 2012;167(2):424–32. https://doi.org/10.1111/j.1365-2133.2012.10965.x.PubMedCrossRef

25.

Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bouwes Bavinck JN, Halevy S, et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013;133(5):1197–204. https://doi.org/10.1038/jid.2012.510.PubMedCrossRef

26.

Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, Roujeau JC, Revuz J. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol. 2006;126(2):272–6. https://doi.org/10.1038/sj.jid.5700068.PubMedCrossRef

27.

• Noe MH, Rosenbach M, Hubbard RA, Mostaghimi A, Cardones AR, Chen JK, et al. Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens-Johnson syndrome/toxic epidermal ncrolysis—ABCD-10Development and validation of a risk prediction model for in-hospital mortality of patients with SJS/TENDevelopment and validation of a risk prediction model for in-hospital mortality of patients with SJS/TEN. JAMA Dermatol. 2019;155(4):448–54. https://doi.org/10.1001/jamadermatol.2018.5605This study utilized a multicenter cohort of 370 patients with SJS/TEN to derive a new risk prediction model called the ABCD-10. The new model give one point for age over 50 years, 10% or greater body surface area of epidermal detachment, and serum bicarbonate less than 20 mmol/L. Two points are given to patients with active cancer status. Three points are given for a history of dialysis within one year of admission. The ABCD-10 model showed good discrimination (AUC 0.816,p= 0.03) but was not significantly different from the SCORTEN (AUC 0.827). PubMedCrossRef

28.

Scott-Lang V, Tidman M, McKay D. Toxic epidermal necrolysis in a child successfully treated with infliximab. Pediatr Dermatol. 2014;31(4):532–4. https://doi.org/10.1111/pde.12029.PubMedCrossRef

29.

Aires DJ, Fraga G, Korentager R, Richie CP, Aggarwal S, Wick J, et al. Early treatment with nonsucrose intravenous immunoglobulin in a burn unit reduces toxic epidermal necrolysis mortality. J Drugs Dermatol. 2013;12(6):679–84.PubMed

30.

• Nizamoglu M, Ward JA, Frew Q, Gerrish H, Martin N, Shaw A, et al. Improving mortality outcomes of Stevens Johnson syndrome/toxic epidermal necrolysis: a regional burns centre experience. Burns. 2018;44(3):603–11. https://doi.org/10.1016/j.burns.2017.09.015This retrospective review of 42 patients with TEN or SJS/TEN overlap who were managed in a burn service over a total of 12 years had a total of 4 deaths compared with 16 predicted by SCORTEN. Investigators concluded that the management in a burn service with aggressive wound care involving debridement and synthetic and biologic dressing seems to have a mortality benefit. PubMedCrossRef

31.

Zhang AJ, Nygaard RM, Endorf FW, Hylwa SA. Stevens-Johnson syndrome and toxic epidermal necrolysis: retrospective review of 10-year experience. Int J Dermatol. https://doi.org/10.1111/ijd.14409.PubMedCrossRef

32.

• Creamer D, Walsh SA, Dziewulski P, Exton LS, Lee HY, Dart JK, et al. U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016;174(6):1194–227. https://doi.org/10.1111/bjd.14530These 2016 guidelines were established to help providers in the management of SJS/TEN. These evidence-based recommendations are graded based on strength of the supporting research and include management of initial presentation, supportive care, and adjuvant therapy. PubMedCrossRef

33.

• McPherson T, Exton LS, Biswas S, Creamer D, Dziewulski P, Newell L, et al. Br J Dermatol. 2018. https://doi.org/10.1111/bjd.17841These 2018 guidelines from the British Association of Dermatologists provide up to date, evidence-based recommendations on the diagnosis and management of SJS/TEN in children (0–12 years) and young people (13–17 years). Their recommendations focus primarily on the acute phase of the disease. They appraise all relevant literature, focusing on recent developments and address practical clinical questions as well as areas of uncertainty. PubMedCrossRef

34.

• Gupta LK, Martin AM, Agarwal N, D’Souza P, Das S, Kumar R, et al. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: an Indian perspective. Indian J Dermatol Venereol Leprol. 2016;82(6):603–25. https://doi.org/10.4103/0378-6323.191134The Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) prepared these guidelines on management of SJS/TEN. Their recommendations include prompt withdrawal of the culprint drug, meticulous supportive care, and judicious and early initiation of moderate to high doses of oral or parenteral corticosteroids. Cyclosporine use was also recommended either alone or in combination with corticosteroids. A multidisciplinary approach to the management of these patients is recommended as helpful. PubMedCrossRef

35.

• Schneider JA, Cohen PR. Stevens-Johnson syndrome and toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures. Adv Ther. 2017;34(6):1235–44. https://doi.org/10.1007/s12325-017-0530-yThis review serves to concisely and comprehensively summarize therapeutic interventions for SJS/TEN. They emphasize supportive care as the mainstay for treatment of these patients. They recommend a case-by-case evaluation of patients for adjuvant therapies, as a standardized management approach for these medications is not yet clear based on current data. PubMedPubMedCentralCrossRef

36.

• Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136(3):323–7 This study is on a consecutive sample of 113 patients with SJS/TEN. After adjusting for confounding variables, the study showed that prompt withdrawal of causative drugs was associated with decreased mortality. The authors’ recommendation is thus to promptly withdraw causative drugs, especially when blisters or erosions appear. PubMedCrossRef

37.

• Yamane Y, Matsukura S, Watanabe Y, Yamaguchi Y, Nakamura K, Kambara T, et al. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--treatment and outcome. Allergol Int. 2016;65(1):74–81. https://doi.org/10.1016/j.alit.2015.09.001This is a retrospective analysis of 52 cases of SJS and 35 cases of TEN, evaluating treatment and outcome. The study showed that treatment with steroid pulse therapy in combination with plasmapheresis and/or immunoglobulin therapy seems to have contributed to prognostic improvement in SJS/TEN. PubMedCrossRef

38.

• Castillo B, Vera N, Ortega-Loayza AG, Seminario-Vidal L. Wound care for Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol. 2018;79(4):764–7 e1. https://doi.org/10.1016/j.jaad.2018.03.032This article is a literature review of SJS/TEN wound care, with the aim to assess the effets of dressing used in wound care and present evidence -based recommendations to assist clinicians in the best approach to wound care. The authors concluded that modern dressings should be part of standard therapy because of less frequent changes and improved patient comfort. PubMedCrossRef

39.

• Rogers AD, Blackport E, Cartotto R. The use of Biobrane((R)) for wound coverage in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Burns. 2017;43(7):1464–72. https://doi.org/10.1016/j.burns.2017.03.016This is a retrospective review of 42 patients with SJS/TEN, where Biobrane was applied in 24 cases. The conclusion was that Biobrane was applied to SJS/TEN patients with more extensive epidermal detachment, but had no significant complications and generallly facilitated epidermal healing at a rate not significantly different from dressing-only treated subjects. PubMedCrossRef

40.

• Spies M, Sanford AP, Aili Low JF, Wolf SE, Herndon DN. Treatment of extensive toxic epidermal necrolysis in children. Pediatrics. 2001;108(5):1162–8 This is case series studying treatment of SJS/TEN in 15 patients. TEN is a rare disease in patients, and the study found that it was successfully managed in a burn center environment, using early debridement and wound coverage with allograft skin as a biological dressing. The management was unchanged in the past 2 decades, indicating an additional need for information and education about the disease. PubMedCrossRef

41.

• Lee HY. Wound management strategies in Stevens-Johnson syndrome/toxic epidermal necrolysis: an unmet need. J Am Acad Dermatol. 2018;79(4):e87–e8. https://doi.org/10.1016/j.jaad.2018.05.1258This brief letter describes the use of conservative versus surgical approaches for wound care in SJS/TEN. It describes side effects of surgical approaches, including postinflammatory hyperpigmentation. PubMedCrossRef

42.

Dorafshar AH, Dickie SR, Cohn AB, Aycock JK, O’Connor A, Tung A, et al. Antishear therapy for toxic epidermal necrolysis: an alternative treatment approach. Plast Reconstr Surg. 2008;122(1):154–60. https://doi.org/10.1097/PRS.0b013e3181773d5d.PubMedCrossRef

43.

Mayes T, Gottschlich M, Khoury J, Warner P, Kagan R. Energy requirements of pediatric patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Nutr Clin Pract. 2008;23(5):547–50. https://doi.org/10.1177/0884533608323434.PubMedCrossRef

44.

• Koh HK, Chai ZT, Tay HW, Fook-Chong S, Choo KJ, Oh CC, et al. Risk factors and diagnostic markers of bacteraemia in Stevens-Johnson syndrome and toxic epidermal necrolysis: a cohort study of 176 patients. J Am Acad Dermatol. 2019. https://doi.org/10.1016/j.jaad.2019.05.096This single-center retrospective cohort study of 176 patients with SJS/TEN found that 29.5% of patients had bacteremia, which was associated with increased mortality, lonter hosptial stay and higher ICU admission. Isolated included Acinetobacter baumannii (27.7%) and Staphylococcus aureus (21.4%). Other clinical factors that were predictive of bacteraemia include: hemoglobin less than or equal to 10g/dL, existing cardiovascular disease, and body surface area greater than 9%. Hypothermia and elevated pro-calcitonin were predictive of blood culture positivity. PubMedCrossRef

45.

Palmieri TL, Greenhalgh DG, Saffle JR, Spence RJ, Peck MD, Jeng JC, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil. 2002;23(2):87–96.PubMedCrossRef

46.

Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69(2):187 e1–16; quiz 203-4. https://doi.org/10.1016/j.jaad.2013.05.002.CrossRef

47.

Meneux E, Paniel BJ, Pouget F, Revuz J, Roujeau JC, Wolkenstein P. Vulvovaginal sequelae in toxic epidermal necrolysis. J Reprod Med. 1997;42(3):153–6.PubMed

48.

Kaser DJ, Reichman DE, Laufer MR. Prevention of vulvovaginal sequelae in Stevens-Johnson syndrome and toxic epidermal necrolysis. Rev Obstet Gynecol. 2011;4(2):81–5.PubMedPubMedCentral

49.

Kaser DJ, Reichman DE, Laufer MR. Prevention of vulvovaginal sequelae in Stevens-Johnson syndrome and toxic epidermal necrolysis. Rev Obstet Gynecol. 2011;4(2):81–5.PubMedPubMedCentral

50.

Chang YS, Huang FC, Tseng SH, Hsu CK, Ho CL, Sheu HM. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea. 2007;26(2):123–9. https://doi.org/10.1097/ICO.0b013e31802eb264.PubMedCrossRef

51.

Yip LW, Thong BY, Lim J, Tan AW, Wong HB, Handa S, et al. Ocular manifestations and complications of Stevens–Johnson syndrome and toxic epidermal necrolysis: an Asian series*. Allergy. 2007;62(5):527–31. https://doi.org/10.1111/j.1398-9995.2006.01295.x.PubMedCrossRef

52.

Morales ME, Purdue GF, Verity SM, Arnoldo BD, Blomquist PH. Ophthalmic manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis and relation to SCORTEN. Am J Ophthalmol. 2010;150(4):505–10.e1. https://doi.org/10.1016/j.ajo.2010.04.026.PubMedCrossRef

53.

Gueudry J, Roujeau J-C, Binaghi M, Soubrane G, Muraine M. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. JAMA Dermatol. 2009;145(2):157–62. https://doi.org/10.1001/archdermatol.2009.540.CrossRef

54.

Van Zyl L, Carrara H, Lecuona K. Prevalence of chronic ocular complications in Stevens-Johnson syndrome and toxic epidermal necrolysis. Middle East Afr J Ophthalmol. 2014;21(4):332–5. https://doi.org/10.4103/0974-9233.142272.PubMedPubMedCentralCrossRef

55.

Sotozono C, Ueta M, Nakatani E, Kitami A, Watanabe H, Sueki H, et al. Predictive factors associated with acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Ophthalmol. 2015;160(2):228–37.e2. https://doi.org/10.1016/j.ajo.2015.05.002.PubMedCrossRef

56.

Sharma N, Thenarasun SA, Kaur M, Pushker N, Khanna N, Agarwal T, et al. Adjuvant role of amniotic membrane transplantation in acute ocular Stevens–Johnson syndrome: a randomized control trial. Ophthalmology. 2016;123(3):484–91. https://doi.org/10.1016/j.ophtha.2015.10.027.PubMedCrossRef

57.

Gregory DG. Treatment of acute Stevens–Johnson syndrome and toxic epidermal necrolysis using amniotic membrane: a review of 10 consecutive cases. Ophthalmology. 2011;118(5):908–14. https://doi.org/10.1016/j.ophtha.2011.01.046.PubMedCrossRef

58.

Kohanim S, Palioura S, Saeed HN, Akpek EK, Amescua G, Basu S, et al. Acute and chronic ophthalmic involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis – a comprehensive review and guide to therapy. II Ophthalmic Disease. Ocular Surf. 2016;14(2):168–88. https://doi.org/10.1016/j.jtos.2016.02.001.CrossRef

59.

Dodiuk-Gad RP, Olteanu C, Feinstein A, Hashimoto R, Alhusayen R, Whyte-Croasdaile S, et al. Major psychological complications and decreased health-related quality of life among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2016;175(2):422–4. https://doi.org/10.1111/bjd.14799.PubMedCrossRef

60.

Patmanidis K, Sidiras A, Dolianitis K, Simelidis D, Solomonidis C, Gaitanis G, et al. Combination of infliximab and high-dose intravenous immunoglobulin for toxic epidermal necrolysis: successful treatment of an elderly patient. Case Rep Dermatol Med. 2012;2012:915314. https://doi.org/10.1155/2012/915314.PubMedPubMedCentralCrossRef

61.

Fischer M, Fiedler E, Marsch WC, Wohlrab J. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol. 2002;146(4):707–9.PubMedCrossRef

62.

Hunger RE, Hunziker T, Buettiker U, Braathen LR, Yawalkar N. Rapid resolution of toxic epidermal necrolysis with anti-TNF-α treatment. J Allergy Clin Immunol. 2005;116(4):923–4. https://doi.org/10.1016/j.jaci.2005.06.029.PubMedCrossRef

63.

Hirahara K, Kano Y, Sato Y, Horie C, Okazaki A, Ishida T, et al. Methylprednisolone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers. J Am Acad Dermatol. 2013;69(3):496–8. https://doi.org/10.1016/j.jaad.2013.04.007.PubMedCrossRef

64.

• Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, et al. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2017;153(6):514–22. https://doi.org/10.1001/jamadermatol.2016.5668This Ssystemic review of 96 studies and 3248 patients with SJS/TEN provides a comprehensive review of systemic immunomodulating therapies compared to with supportive care. Mortality benefits expressed as OR were found for cyclosporine and glucocoriticoids in unstratified models. PubMedPubMedCentralCrossRef

65.

Aoki Y, Kao PN. Cyclosporin A-sensitive calcium signaling represses NFkappaB activation in human bronchial epithelial cells and enhances NFkappaB activation in Jurkat T-cells. Biochem Biophys Res Commun. 1997;234(2):424–31. https://doi.org/10.1006/bbrc.1997.6658.PubMedCrossRef

66.

Roujeau JC, Bastuji-Garin S. Systematic review of treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality. Ther Adv Drug Saf. 2011;2(3):87–94. https://doi.org/10.1177/2042098611404094.PubMedPubMedCentralCrossRef

67.

Paradisi A, Abeni D, Bergamo F, Ricci F, Didona D, Didona B. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol. 2014;71(2):278–83. https://doi.org/10.1016/j.jaad.2014.04.044.PubMedCrossRef

68.

• Wang CW, Yang LY, Chen CB, Ho HC, Hung SI, Yang CH, et al. Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018;128(3):985–96. https://doi.org/10.1172/JCI93349This randomized, controlled trial of 96 patients with SJS/TEN found that Eetanercept decreased the SCORTEN-predicted mortality rate compared to with corticosteroids. Investigators also observed a significantly reduced skin-healing time in the moderate-to-severely affected patients (p = 0.010). Enteracept groups had reduced granulysin in blister fluids and plasma and an increased Treg cell population (p = 0.002) - —providing insights on the potential mechanism-of-action. PubMedPubMedCentralCrossRef

69.

Shah R, Chen ST, Kroshinsky D. Use of cyclosporine for the treatment of Steven Johnson syndrome/ toxic epidermal necrolysis. J Am Acad Dermatol. 2019. https://doi.org/10.1016/j.jaad.2018.09.063.

70.

• Han F, Zhang J, Guo Q, Feng Y, Gao Y, Guo L, et al. Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study. J Crit Care. 2017;42:65–8. https://doi.org/10.1016/j.jcrc.2017.07.002This prospective observational study evaulated the response of 28 patients to plasmapheresis tehrapy after admission for SJS/TEN. Severity of disease and efficacy of treatments were evaluated by the severity-of-illness score for TEN. Results indicated that plasmapheresis may be superior to conventional therapy, and that plasmapheresis alone may be more beneficial than combination therapies. PubMedCrossRef

71.

Morici MV, Galen WK, Shetty AK, Lebouef RP, Gouri TP, Cowan GS, et al. Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. J Rheumatol. 2000;27(10):2494–7.PubMed

72.

Valeyrie-Allanore L, Wolkenstein P, Brochard L, Ortonne N, Maitre B, Revuz J, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010;163(4):847–53. https://doi.org/10.1111/j.1365-2133.2010.09863.x.PubMedCrossRef

73.

Furubacke A, Berlin G, Anderson C, Sjoberg F. Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis? Intensive Care Med. 1999;25(11):1307–10.PubMedCrossRef

74.

Narita YM, Hirahara K, Mizukawa Y, Kano Y, Shiohara T. Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: is cytokine expression analysis useful in predicting its therapeutic efficacy? J Dermatol. 2011;38(3):236–45. https://doi.org/10.1111/j.1346-8138.2010.01154.x.PubMedCrossRef

75.

Kostal M, Blaha M, Lanska M, Kostalova M, Blaha V, Stepanova E, et al. Beneficial effect of plasma exchange in the treatment of toxic epidermal necrolysis: a series of four cases. J Clin Apher. 2012;27(4):215–20. https://doi.org/10.1002/jca.21213.PubMedCrossRef

76.

Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. Int J Dermatol. 2015;54(1):108–15. https://doi.org/10.1111/ijd.12423.PubMedCrossRef

77.

Del Pozzo-Magana BR, Lazo-Langner A, Carleton B, Castro-Pastrana LI, Rieder MJ. A systematic review of treatment of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Popul Ther Clin Pharmacol. 2011;18:e121–33.PubMed

78.

Michaels B. The role of systemic corticosteroid therapy in erythema multiforme major and Stevens-Johnson syndrome: a review of past and current opinions. J Clin Aesthet Dermatol. 2009;2(3):51–5.PubMedPubMedCentral

79.

Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58(1):33–40. https://doi.org/10.1016/j.jaad.2007.08.039.PubMedCrossRef

80.

• Ng QX, De Deyn M, Venkatanarayanan N, Ho CYX, Yeo WS. A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis. J Inflamm Res. 2018;11:135–42. https://doi.org/10.2147/jir.S160964This meta-analysis of 9 studies demonstrated significant mortality reduction with a standardized mortality ratio of 0.320 (p = 0.002). Cyclosporine was well tolerated with few adverse efects. There was observed publication bias (p = 0.0467). PubMedPubMedCentralCrossRef

81.

• Chen Y-T, Hsu C-Y, Chien Y-N, Lee W-R, Huang Y-C. Efficacy of cyclosporine for the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: systemic review and meta-analysis. Dermatol Sin. 2017;35(3):131–7. https://doi.org/10.1016/j.dsi.2017.04.004This systemic review of 7 studies compared mortality rates for patients receiving cyclosporine vs those receiving IVIg (4 studies), corticosteroids (1 study), combination therapy consisting of steroids and cyclophosphamiden 1 study), and supportive therapy (2 studies). Cyclosporine had significantly higher mortality benefit compared to with all other groups. CrossRef

82.

Kirchhof MG, Miliszewski MA, Sikora S, Papp A, Dutz JP. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol. 2014;71(5):941–7. https://doi.org/10.1016/j.jaad.2014.07.016.PubMedCrossRef

83.

• Gonzalez-Herrada C, Rodriguez-Martin S, Cachafeiro L, Lerma V, Gonzalez O, Lorente JA, et al. Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. J Invest Dermatol. 2017;137(10):2092–100. https://doi.org/10.1016/j.jid.2017.05.022This retrospective study compared the outcomes at two different burn units in Madrid over the period from 2001 to 2015. On unit utilized cyclosporine while the tother used non-cyclosporine regimens. Investigators also observed outcomes for a case series of 49 patients who were treated in other regions of Madrid and an additional five case series. Investigators found that cyclosporine consistently reduced mortality. PubMedCrossRef

84.

Reese D, Henning JS, Rockers K, Ladd D, Gilson R. Cyclosporine for SJS/TEN: a case series and review of the literature. Cutis. 2011;87(1):24–9.PubMed

85.

• St John J, Ratushny V, Liu KJ, Bach DQ, Badri O, Gracey LE, et al. Successful use of cyclosporin A for Stevens-Johnson syndrome and toxic epidermal necrolysis in three children. Pediatr Dermatol. 2017;34(5):540–6. https://doi.org/10.1111/pde.13236This case series explored the efficacy of Ccyclosporine A in the treatment of SJS/TEN in three pediatric patients. Treatment with Ccyclosporine A for these patients was successful, with an average of 2.2 days to cessation of disease (range 1.5–-3 days) and 13 days to re-epithelialization (range 10–-15 days). Average hospital stay was 11.7 days (range 4–-19 days). PubMedCrossRef

86.

• Poizeau F, Gaudin O, Le Cleach L, Duong TA, Hua C, Hotz C, et al. Cyclosporine for epidermal necrolysis: absence of beneficial effect in a retrospective cohort of 174 patients-exposed/unexposed and propensity score-matched analyses. J Invest Dermatol. 2018;138(6):1293–300. https://doi.org/10.1016/j.jid.2017.12.034This retrospective review of 174 patients with SJS/TEN from 2005–-2016 found no statistically significant beneficial effect on mortality, duration of progression and re-epithelialization status at day 5 or 10 for non-mucosal and mucosal skin, respectively. PubMedCrossRef

87.

Singh GK, Chatterjee M, Verma R. Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid. Indian J Dermatol Venereol Leprol. 2013;79(5):686–92. https://doi.org/10.4103/0378-6323.116738.PubMedCrossRef

88.

• Curtis JA, Christensen LC, Paine AR, Collins Brummer G, Summers EM, Cochran AL, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis treatments: an Internet survey. J Am Acad Dermatol. 2016;74(2):379–80. https://doi.org/10.1016/j.jaad.2015.08.033The investigators of this study surveyed 290 providers (of 1927 providers sent the survey link) who had treated a patient with SJS/TEN in the past year. The survey showed that the majority of providers don’t use systemic steroids for any classification of SJS/TEN. Most preferred IVIG in SJS/TEN overlap or TEN, but some did not use IVIG in SJS cases. Cyclosporine was the most frequently used alternative therapy. Most providers did not debride the skin and preferred petrolatum-impregnated gauze and nonadherent dressings with nanocrystalline silver. PubMedCrossRef

89.

Trent J, Halem M, French LE, Kerdel F. Toxic epidermal necrolysis and intravenous immunoglobulin: a review. Semin Cutan Med Surg. 2006;25(2):91–3. https://doi.org/10.1016/j.sder.2006.04.004.PubMedCrossRef

90.

Prins C, Vittorio C, Padilla RS, Hunziker T, Itin P, Forster J, et al. Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study. Dermatology. 2003;207(1):96–9. https://doi.org/10.1159/000070957.PubMedCrossRef

91.

Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatrics. 2003;112(6 Pt 1):1430–6. https://doi.org/10.1542/peds.112.6.1430.PubMedCrossRef

92.

Jagadeesan S, Sobhanakumari K, Sadanandan SM, Ravindran S, Divakaran MV, Skaria L, et al. Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian J Dermatol Venereol Leprol. 2013;79(4):506–11. https://doi.org/10.4103/0378-6323.113080.PubMedCrossRef

93.

Zhu QY, Ma L, Luo XQ, Huang HY. Toxic epidermal necrolysis: performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China. J Burn Care Res. 2012;33(6):e295–308. https://doi.org/10.1097/BCR.0b013e318254d2ec.PubMedCrossRef

94.

• Ye LP, Zhang C, Zhu QX. The effect of intravenous immunoglobulin combined with corticosteroid on the progression of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis. PLoS One. 2016;11(11):e0167120. https://doi.org/10.1371/journal.pone.0167120This meta-analysis of 26 studies including 628 patients evaluated the efficacy of IVIG combined with corticosteroids on the progression of SJS/TEN. They found that this combination therapy could reduce recovery time, especially in Asian patients. However, its impact on reducing mortality was not significant. PubMedPubMedCentralCrossRef

95.

Zarate-Correa LC, Carrillo-Gomez DC, Ramirez-Escobar AF, Serrano-Reyes C. Toxic epidermal necrolysis successfully treated with infliximab. J Investig Allergol Clin Immunol. 2013;23(1):61–3.PubMed

96.

Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998;352(9140):1586–9. https://doi.org/10.1016/S0140-6736(98)02197-7.PubMedCrossRef

97.

Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149–53. https://doi.org/10.1046/j.1523-1747.2000.00061.x.PubMedCrossRef

98.

• Morita K, Matsui H, Michihata N, Fushimi K, Yasunaga H. Association of early systemic corticosteroid therapy with mortality in patients with Stevens-Johnson syndrome or toxic epidermal necrolysis: a retrospective cohort study using a nationwide claims database. Am J Clin Dermatol. 2019;30:30 This large retrospective cohort study of 1846 patients evaluated the association of early systemic corticosteroid therapy with mortality in patients with SJS/TEN. Their results indicated that eary systemic corticosteroid therapy was not associated with lower in-hospital mortality.

99.

• Liu W, Nie X, Zhang L. A retrospective analysis of Stevens-Johnson syndrome/toxic epidermal necrolysis treated with corticosteroids. Int J Dermatol. 2016;55(12):1408–13. https://doi.org/10.1111/ijd.13379This study retrospective analysis of 70 patients with SJS/TEN evaluated a response to treatment with corticosteroids. The study supports the use of corticosteroids in SJS/TEN as it was associated with lower mortality rate and serum albumin levels. Investigators conclude that corticosteroids should be administered in accordance with disease severity, age, underlying diseaes, serum albumin level, and concurrent antimicrobial therapy. PubMedCrossRef

100.

Roongpisuthipong W, Prompongsa S, Klangjareonchai T. Retrospective analysis of corticosteroid treatment in Stevens-Johnson syndrome and/or toxic epidermal necrolysis over a period of 10 years in Vajira Hospital, Navamindradhiraj University, Bangkok. Dermatol Res Pract. 2014;2014:237821. https://doi.org/10.1155/2014/237821.PubMedPubMedCentralCrossRef

101.

• Lee HY, Fook-Chong S, Koh HY, Thirumoorthy T, Pang SM. Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: retrospective analysis of a cohort treated in a specialized referral center. J Am Acad Dermatol. 2017;76(1):106–13. https://doi.org/10.1016/j.jaad.2016.07.048This retrospective analysis of 44 patients sought to evaluate the impact of cyclosporine on hospital mortality in patients with SJS/TEN. 24 patients received cyclosporine and 20 were treated supportively. SCORTEN predicted 7.5 deaths in the cyclosporine group, and 3 were observed. SCORTEN predicted 5.9 deaths in the supportive group, and 6 were observed. Thus, the standardized mortality ratio of SJS/TEN treated with cyclosporine was 0.42. They concluded that the use of cyclosporine may improve mortality in SJS/TEN. PubMedCrossRef

102.

• Lee HY, Lim YL, Thirumoorthy T, Pang SM. The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre. Br J Dermatol. 2013;169(6):1304–9. https://doi.org/10.1111/bjd.12607This retrospective cohort study of 42 patients sought to investigate the association between type of immune modulatory treatment administered and prognosis of patient. They found apparent reduced mortality in patients treated with combination IVIG and corticosteroid therapy. PubMedCrossRef

103.

Chan L, Cook DK. A 10-year retrospective cohort study of the management of toxic epidermal necrolysis and Stevens-Johnson syndrome in a New South Wales state referral hospital from 2006 to 2016. Int J Dermatol. 2019;25:25.

104.

Chen J, Wang B, Zeng Y, Xu H. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases. Eur J Dermatol. 2010;20(6):743–7. https://doi.org/10.1684/ejd.2010.1077.PubMedCrossRef

105.

Paquet P, Jennes S, Rousseau AF, Libon F, Delvenne P, Piérard GE. Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. Burns. 2014;40(8):1707–12. https://doi.org/10.1016/j.burns.2014.01.027.PubMedCrossRef

Titel: Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: a Review and Update
verfasst von: Jennifer L. Coias
Laila F. Abbas
Adela R. Cardones
Publikationsdatum: 06.12.2019
Verlag: Springer US
Erschienen in: Current Dermatology Reports / Ausgabe 4/2019
Elektronische ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-019-00275-0

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

22.04.2024 | DGIM 2024 | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: a Review and Update

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Inpatient Management of Mucocutaneous GVHD

Wound Care in the Developing World - Gaps, Opportunities, and Realities

Inpatient Management of Autoimmune Blistering Diseases: an Update, Review, and Practical Guide

Paraneoplastic Syndromes for the Inpatient Dermatologist

Photoallergic Contact Dermatitis

New Strategies for Prevention and Treatment of Insect Bite Hypersensitivity in Horses

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie